13D Filing: Starboard Value LP and Depomed Inc (DEPO)

Page 15 of 23

Page 15 of 23 – SEC Filing

The following constitutes
Amendment No. 9 to the Schedule 13D filed by the undersigned (“Amendment No. 9”). This Amendment No. 9 amends the Schedule
13D as specifically set forth herein.

Item 3. Source and Amount of Funds or Other Consideration.

Item 3 is hereby amended
and restated to read as follows:

The Shares purchased
by each of Starboard V&O Fund, Starboard S LLC and Starboard C LP and held in the Starboard Value LP Account were purchased
with working capital (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business)
in open market purchases, except as otherwise noted, as set forth in Schedule A, which is incorporated by reference herein. The
aggregate purchase price of the 3,456,984 Shares beneficially owned by Starboard V&O Fund is approximately $50,015,287, excluding
brokerage commissions. The aggregate purchase price of the entered into over-the-counter forward purchase contracts providing for
the purchase of 194,730 Shares by Starboard V&O Fund is approximately $3,504,653, excluding commissions. The aggregate purchase
price of the 430,843 Shares beneficially owned by Starboard S LLC is approximately $6,393,502, excluding brokerage commissions.
The aggregate purchase price of the 239,310 Shares beneficially owned by Starboard C LP is approximately $3,484,167, excluding
brokerage commissions. The aggregate purchase price of the 413,428 Shares held in the Starboard Value LP Account is approximately
$6,204,115, excluding brokerage commissions. The 3,252 Shares beneficially owned by Mr. Molinelli represent shares that were granted
to Mr. Molinelli by the Issuer in his former capacity as a director of the Issuer.

Item 5. Interest in Securities of the Issuer.

Items 5(a) – (c) are hereby amended
and restated to read as follows:

The aggregate percentage
of Shares reported owned by each person named herein is based upon 63,516,077 Shares outstanding, as of March 16, 2018, which is
the total number of Shares outstanding as reported in the Issuer’s definitive proxy statement on Schedule 14A filed with
the Securities and Exchange Commission on March 27, 2018.

A. Starboard V&O Fund
(a) As of the close of business on April 5, 2018, Starboard V&O Fund beneficially owned 3,651,714
Shares, including 194,730 Shares underlying certain forward purchase contracts.

Percentage: Approximately 5.7%

(b) 1. Sole power to vote or direct vote: 3,651,714
2. Shared power to vote or direct vote: 0
3. Sole power to dispose or direct the disposition: 3,651,714
4. Shared power to dispose or direct the disposition: 0
(c) The transactions in the Shares by Starboard V&O Fund since the filing of Amendment No. 8 to
the Schedule 13D are set forth in Schedule A and are incorporated herein by reference.
15

Follow Assertio Therapeutics Inc (NASDAQ:ASRT)

Page 15 of 23